OBJECTIVES: Studies evaluating the correlation between the widely used Simple Endoscopic Score for Crohn ' s disease (SES-CD) and noninvasive markers are scarce. The aim of this study was to evaluate the correlation between the SES-CD and fecal calprotectin, C-reactive protein (CRP), blood leukocytes, and the Crohn ' s disease activity index (CDAI).
INTRODUCTION
Th e assessment of Crohn ' s disease (CD) activity is based on a combination of symptoms, clinical fi ndings, and endoscopy. However, there is oft en an insuffi cient correlation between these diagnostic elements (1 -6) . Although ileocolonoscopy is considered the gold standard for assessment of intestinal infl ammation, it has the disadvantage of being invasive, timeconsuming, expensive, and sometimes uncomfortable for patients.
To overcome these limitations, several laboratory markers have been evaluated regarding their performance for monitoring CD activity. Active infl ammation in CD patients is associated with an acute-phase reaction and migration of leukocytes to the gut. Th ereby, various proteins can be measured in serum Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn ' s Disease (SES-CD) than CRP, Blood Leukocytes, and the CDAI and feces (7) . C-reactive protein (CRP), produced by hepatocytes upon stimulation by proinfl ammatory cytokines, such as interleukins 1 and 6, has been found to be associated with clinical and endoscopic activity in infl ammatory bowel disease (IBD) (8 -10) . Fecal calprotectin represents 60 % of cytosolic proteins in granulocytes. Th e amount of calprotectin in feces is therefore proportional to the neutrophil migration to the gastrointestinal mucosa. Fecal calprotectin is stable against degradation for up to 1 week at room temperature (11) . It accurately distinguishes IBD from non-IBDs such as irritable bowel syndrome (12) . Several publications in pediatric and adult cohorts have demonstrated a correlation of the amount of fecal calprotectin with the severity of mucosal infl ammation (13 -15) . A good correlation between fecal calprotectin and the Crohn ' s Disease Endoscopic Index of Severity has already been demonstrated (16, 17) . However, the Crohn ' s Disease Endoscopic Index of Severity is cumbersome to complete and time-consuming in clinical practice; therefore, the Simple Endoscopic Score for Crohn ' s disease (SES-CD) was developed and validated in 2004 (18) . Th e SES-CD demonstrated a strong correlation with the Crohn ' s Disease Endoscopic Index of Severity (correlation coeffi cient r = 0.920) and an excellent inter-observer reliability ( κ coeffi cients 0.791 -1.000). Compared with the Crohn ' s Disease Endoscopic Index of Severity, the SES-CD is much easier to perform and thus more frequently used in clinical practice (18) . So far, data regarding the correlation of fecal calprotectin with SES-CD are scarce, and there is especially a paucity of studies evaluating the endoscopic disease activity with calprotectin in relation to other biomarkers (19, 20) . Knowledge about the test performance of diff erent biomarkers to discriminate classes of infl ammatory activity is important for the early detection of relapses and for tailoring the individual therapy. Th is appraisal is supported by recently published papers claiming that the optimal therapeutic target to modify disease course in IBD patients should not only be clinical remission, but also mucosal healing; this last item is associated with a reduced need for surgery and hospitalization in CD patients (21, 22) .
We hypothesized that fecal calprotectin would be superior to the Crohn ' s disease activity index (CDAI), CRP, and blood leukocytes to discriminate the endosopic disease activity.
Th us, we aimed to answer the following questions in this study: fi rst, is there any noninvasive marker that is able to discriminate between inactive, mild, moderate, and severe endoscopic activity? And second, what is the overall test accuracy of the CDAI and the various biomarkers for the detection of endoscopically active disease?
METHODS

Participants
Of 173 adult outpatients and inpatients with previously confi rmed diagnosis of CD referred for colonoscopy at the Departments of Gastroenterology of the University Hospitals Bern and Basel between March 2006 and June 2008, 122 patients were included (71 % ). Th ey were diagnosed on the basis of standard clinical, endoscopic, and histological criteria (23) . Th e study was conducted with approval of the local ethics committees. Th e local investigators fi rst instructed patients, and then they were provided with a fecal specimen collection set consisting of two fecal tubes (one tube for 1 ml, order number 55478, Sarstedt AG, N ü rnbrecht Germany, and one tube for stool culture and Clostridium diffi cile toxin assay). Th e collection of fecal specimens was carried out by patients themselves. Th e fecal specimens from the outpatients were shipped by mail to the laboratory. In inpatients, the fecal collection set was prepared by a trained nurse and then sent to the laboratory. Th e fecal samples for bacterial analysis were processed immediately aft er receipt, whereas fecal samples for calprotectin were stored at − 40 ° C until analysis. Blood samples for the measurement of a full blood count and CRP were taken within 3 days before endoscopy. Ten of the included CD patients (8 % ) underwent an upper endoscopy (because of upper abdominal complaints) on the same day when ileocolonoscopy was performed, no CD-related lesions or refl ux-associated lesions could be detected in this subgroup.
Inclusion criteria . Disease duration >3 months, complete ileocolonoscopy including biopsies (at least two biopsies from terminal ileum and four colonic biopsies from aff ected regions), age 18 -85 years, fecal samples delivered from 3 days to 1 day before ileocolonoscopy (bowel preparation was not started until the fecal specimen was delivered).
Exclusion criteria . Incomplete ileocolonoscopy (ileum not intubated), infectious enterocolitis (positive stool culture for Salmonella, Shigella, Campylobacter, positive C. diffi cile toxin A + B assay, cytomegalovirus positive in conventional histology or in immunohistochemistry), colorectal cancer, ulcerative colitis, indeterminate colitis, urinary incontinence (risk of contamination of fecal samples), inability to collect fecal samples, pregnancy, history of extensive bowel resection (ileosigmoidostomy and ileorectostomy), ostomy, symptoms related mainly to perianal penetrating disease, known CD of the esophagus or the stomach or the duodenum, regular intake of aspirin and / or non-steroidal anti-infl ammatory drugs (NSAID) (more than two tablets per week). Of a total of 173 screened CD patients, 51 were excluded: 8 because of incomplete ileocolonoscopy (strictures that could not be passed aft er balloon dilation), 3 for not delivering fecal samples on time, 3 for known and active CD of upper gastrointestinal tract, one for intake of NSAID, one for positive C. diffi cile toxin assay, and 35 for denial to participate in the study.
Endoscopic disease activity
During the study period, 18 patients underwent ileocolonoscopy twice, therefore 140 endoscopies were performed in 122 patients. Indications for endoscopy were clinically active disease (fl are) ( n = 76, 54 % ), assessment of endoscopic activity aft er medical treatment ( n = 45, 32 % ), dysplasia surveillance for long-standing disease ( n = 15, 11 % ), and stricture dilation ( n = 4, 3 % ). Five experienced board certifi ed gastroenterologists (AMS, CB, AS, SV, and FS), each of them with at least 5 years
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of experience in performing ileocolonoscopy, performed the endoscopies and graded the fi ndings according to the SES-CD.
For calculating the SES-CD, the intestine was divided into fi ve segments: the ileum, the right colon, the transverse colon, the left colon, and the rectum. Th e degree of disease involvement in each of the fi ve segments was determined by the assessment of four parameters: presence and size of ulcers (score 0 -3), extent of ulcerated surface (score 0 -3), extent of aff ected surface (score 0 -3), and presence and type of narrowing (score 0 -3) (18) . Th e sum of the score for each endoscopic variable ranges from 0 to 15, except for stenosis, where it varies between 0 and 11, because 3 represents a stenosis through which a colonoscope cannot be passed, and therefore can be observed only once. Th e lowest possible SES-CD was 0, representing an intestine without any lesions, the highest possible score was 56 points. Th e clinical disease activity was assessed by the measurement of the CDAI by a physician not performing the colonoscopy. All gastroenterologists performing the endoscopies were unaware of the results of the CDAI, fecal calprotectin, CRP, and blood leukocytes to avoid bias.
Th e controls were healthy persons from the clinical and laboratory staff willing to provide blood and fecal samples. All healthy controls were free of symptoms and had no history of abdominal complaints. Th e control group did not undergo endoscopy. Except for birth control pills in 13 women, these persons were not on any regular medication.
So far there exists no defi nition on how to defi ne endoscopic remission and diff erent levels of activity using the SES-CD. Upon a consensus conference within our study group we defi ned ( a priori ) the SES-CD activity levels as follows:
Inactive (remission) 0 -3 Mild activity 4 -10 Moderate activity 11 -19 High activity ≥ 20 points.
Fecal calprotectin
Fecal calprotectin was measured by a quantitative enzymelinked immunosorbent assay (PhiCal Test, purchased from Medical Instrument Corporation, Solothurn, Switzerland, ArtNo. 006, the test is delivered by CALPRO AS, Oslo, Norway). Th is sandwich enzyme-linked immunosorbent assay (ELISA) measures quantitative calprotectin. Fecal specimens were diluted at 1:2500. Th e scientist (MT) carrying out the analyses was blinded to the patient names, the clinical and endoscopic fi ndings. All fecal samples were processed within 72 h aft er collection. Th e assays were carried out according to the test instructions. Enzyme-linked immunosorbent assay plates were read on a Spectra mini reader (TECAN, Männedorf, Switzerland) at an optical density of 450 nm. According to the manufacturer, the calprotectin cutoff level representing a positive value was ≥ 50-μ g calprotectin / g feces.
CRP and blood leukocytes
Blood leukocytes (normal range 2.6 -7.8 g / l), hemoglobin (normal range for women 120 -160 g / l, for men 140 -180 g / l), as well as CRP (upper limit of normal < 5 mg / l) were determined as routine laboratory values within 3 days before endoscopy.
Statistical analysis
Data were listed on an Excel sheet (Microsoft Excel 2003; Microsoft Switzerland, Wallisellen, Switzerland), statistical analyses were carried out with a statistical package program (Stata vs. 9, College Station, TX, USA). Results of numerical data are presented as mean ± s.d. and range. Normal distribution of data was tested using a Normal-QQ-Plot. Fisher ' s exact test (two-sided) or the χ 2 tests were used to explore associations of categorical data in two independent groups. Th e Wilcoxon ' s rank-sum test was used to explore associations of non-parametric numerical data in two independent groups and the t -test was used for parametric numerical data. A P < 0.05 was considered statistically signifi cant. A Bonferroni adjustment was carried out in case of multiple testing. Th e association between endoscopic disease activity with the CDAI, fecal calprotectin, CRP, and blood leukocytes was assessed by the determination of Spearman ' s rank correlation coeffi cient ( r ) for non-parametric correlations. Th e test characteristics are presented as sensitivity, specifi city, positive and negative predictive values (SENS, SPEC, PPV, and NPV), and overall accuracy. Th e overall accuracy is calculated by addition of the true-positive and true-negative test results divided by all tests (a + d) / (a + b + c + d) and admits the comparative evaluation of the various tests. An receiver operating characteristic analysis was carried out to determine the test characteristics of noninvasive parameters for the detection of endoscopically active disease. A power analysis revealed that a sample size of 17 in each of the four subgroups of endoscopic disease activity (total n = 68) would have 90 % power to detect a diff erence in the mean calprotectin between the subgroups, using a Mann -Whitney rank-sum test with a 0.05 two-sided signifi cance level.
RESULTS
Patients and controls characteristics
Th e clinical characteristics of the patients and healthy controls are shown in Table 1 . Disease phenotypes were grouped according to the Montreal classifi cation (24) . As therapy regimens overlapped, the total counts 131 % .
Th e baseline clinical and laboratory characteristics of CD patients and controls are demonstrated in Table 2 . Calprotectin, CRP, and blood leukocytes were signifi cantly higher in CD patients compared with controls (all P < 0.001).
Correlation of the SES-CD with fecal calprotectin, CRP, blood leukocytes, and the CDAI Th e SES-CD correlated signifi cantly with levels of fecal calprotectin (Spearman ' s rank correlation coeffi cient r = 0.75), CRP ( r = 0.53), blood leukocytes ( r = 0.42), and the CDAI ( r = 0.38). For all items a P < 0.01 was found. Figure 1 demonstrates the correlation between the SES-CD and fecal calprotectin with a scatter plot. Table 3 summarizes the relationship between the diff erent subgroups of SES-CD with their corresponding CDAI, fecal calprotectin, CRP, and blood leukocytes (values given as mean ± s. d. and range). Briefl y, calprotectin was the only biomarker able to discriminate the four subgroups of SES-CD ( P < 0.001 for discriminating inactive from mild disease, P = 0.008 for discriminating mild from moderate, and P < 0.001 for discriminating moderate from high endoscopic activity). Th is fi nding is further illustrated by Figure 2 . Calprotectin (cutoff 50 μ g / g) was elevated in 11 out of 26 (42 % ) of patients with inactive disease compared with 101 out of 114 (89 % ) with active disease. In patients with mild activity, elevated calprotectin was found in 32 out of 40 (80 % ) of patients compared with 24 out of 27 (89 % ) of patients with moderate and 45 out of 47 (96 % ) with severe disease activity. Th e CDAI could neither discriminate inactive from mild nor mild from moderate endoscopic activity. Th e only signifi cance in the CDAI was found for discrimination of moderate vs. highly active endoscopic disease ( P < 0.001). CRP was able to discriminate mild from moderate and moderate vs. high endoscopic activity ( P = 0.013 and P = 0.019), however, CRP failed to discriminate inactive from mildly active endoscopic disease. A diff erence in the blood leukocyte counts was detected only between moderate vs. highly active endoscopic disease. We assessed steroid use between the groups. A total of 19 CD patients (16 % ) were treated with corticosteroids at the time of inclusion (0 with endoscopically inactive disease, 2 with mild, 3 with moderate, and 14 with severe disease). Th ere was a trend for more frequent steroid use in the group with severe endoscopic disease (3 out of 27 vs. 14 out of 47, P = 0.066).
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Effect of disease location and behavior on the noninvasive CD-activity parameters
We were wondering about the correlation of the noninvasive disease-activity parameters stratifi ed according to disease location and behavior.
Crohn ' s disease was identifi ed in 29 % ( n = 41) in the terminal ileum (L1), in 19 % ( n = 26) in the colon (L2) and in 52 % ( n = 73) in the terminal ileum and colon. Table 4 describes the relationship between the noninvasive diasease-activity markers and the disease location. In summary, ileocolonic CD (L3) was associated with signifi cantly higher mean calprotectin compared with CD located in the terminal ileum (L1). However, the CDAI, CRP, and blood leukocytes did not diff er when stratifi ed according to the disease location.
We further investigated the noninvasive disease-activity markers stratifi ed according to the disease phenotype. A non-stricturing, non-penetrating (B1) phenotype was identifi ed in 65 (46 % ) patients, whereas 33 (24 % ) were diagnosed with a stricturing (B2) and 20 (15 % ) with a penetrating phenotype (B3). Perianal penetrating disease was found in 8 (6 % ) of B1 patients, in 8 (6 % ) of B2, and in 6 (4 % ) of B3 patients. As the patient group with perianal penetrating disease per phenotype ( n = 8 for B1, n = 8 for B2, and n = 6 for B3) is too small for a comparative analysis, these patients were summarized under " perianal disease " ( n = 22, 15 % ). In contrast to the stratifi cation according disease location, we found no correlation between the noninvasive disease-activity markers and the disease phenotype (data not shown).
We further analyzed Spearman ' s rank correlation coeffi cients between fecal calprotectin and SES-CD stratifi ed according disease location, which are presented as follows: L1: n = 41, r = 0.649, P < 0.001; L2: n = 26, r = 0.702, P < 0.001; L3: n = 73, 
DISCUSSION
Th is study demonstrates that in CD fecal calprotectin correlates closely with the endoscopic disease activity and was the only biomarker that could discriminate inactive from mild, moderate, and highly active disease. Second, the CDAI (cutoff ≥ 150) presented the worst overall accuracy for detection of endoscopically active disease. Several groups have already shown that fecal calprotectin correlates to the endoscopic disease activity in pediatric and adult CD patients (12, 14, 15) . However, studies assessing the correlation between a grouped endoscopic disease activity according the SES-CD and fecal calprotectin are scarce. Sipponen et al. (20) evaluated the correlation of fecal calprotectin and lactoferrin with the SES-CD in a cohort of 61 CD patients (87 ileocolonoscopies) and applied a grouped assessment of endoscopic activity to a certain extent comparable with our classifi cation (SES-CD: inactive 0 -3, mild or moderate 4 -14, and severe ≥ 15) . Th ey found that fecal calprotectin could discriminate inactive from mild to moderate and highly active endoscopic disease. Our results in a twice-larger cohort are in accordance with their fi ndings regarding the good performance of fecal calprotectin to discriminate between diff erent infl ammatory activities. Comparable with our fi ndings, the correlation between SES-CD and calprotectin was closer than with CRP, blood leukocytes, and the CDAI.
Langhorst et al. (15) evaluated in a cohort of 43 adult CD patients fecal calprotectin besides lactoferrin, poly-morphonuclear-elastase, CRP, and clinical indices . Th ey calculated an endoscopic disease activity by means of a four-degree system (comparable with our arrangement with the SES-CD) and reported a signifi cant correlation of calprotectin with the binary ordered (active vs. non-active) endoscopic disease activity. No correlation of calprotectin or any other fecal marker was reported with the subclasses of endoscopic infl ammatory activity. Comparable with our data, they documented signifi cant correlations of the endoscopic disease activity with fecal calprotectin, CRP, and the CDAI. However, their endoscopic activity, calprotectin correlation coeffi cient ( r = 0.35) is lower than ours ( r = 0.75), which is probably related to our larger patient cohort and our inclusion of a relatively high proportion of patients r = 0.795, P < 0.001. In summary, the best correlation between fecal calprotectin and SES-CD was found for ileocolonic CD.
Th e coeffi cients stratifi ed according to the disease behavior present as follows: B1: n = 65, r = 0.774, P < 0.001; B2: n = 33, r = 0.706, P < 0.001; B3: n = 20, r = 0.718, P < 0.001. In summary, the best correlation between SES-CD and fecal calprotectin was found for infl ammatory CD.
Test characteristics of the CDAI, fecal calprotectin, CRP, and blood leukocytes in predicting endoscopically active disease
Th e test performance (given by sensitivity / specifi city / positive and negative predictive values in percent) of the CDAI, fecal calprotectin with two cutoff s, CRP, and blood leukocytes in predicting endoscopically active disease (SES-CD ≥ 4) is demonstrated in Table 5 .
In summary, calprotectin with a cutoff of ≥ 70 μ g / g had the best overall accuracy (87 % ) for the detection of endoscopically active disease, followed by calprotectin with the ≥ 50 μ g / g cutoff (accuracy 84 % ), then elevated CRP (accuracy 66 % ), then blood leukocytosis (accuracy 54 % ), and fi nally the CDAI ≥ 150 (accuracy 40 % ). Leukocytes (g / l) 9.1 ± 3.4 1.5 -18.8 5.4 ± 1.9 3.5 -12.4 < 0.001 CD, Crohn's disease; CDAI, Crohn's disease activity index; CRP, C-reactive protein; HC, healthy controls; NA, not available; s.d., standard deviation; SES-CD, simple endoscopic score for Crohn's disease. Calprotectin, CRP, and blood leukocytes were signifi cantly higher in CD patients compared with controls (all P < 0.001). 
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with high infl ammatory activity. Canani et al. (14) assessed in a pediatric cohort of 26 CD patients the correlation between fecal calprotectin, endoscopic activity, and mucosal infl ammation using a histopathological score . Fecal calprotectin demonstrated a good correlation with the histological and endoscopic grade of colonic infl ammation. Again, a correlation of calprotectin with the diff erent degrees of endoscopic activity is not reported. Jones et al. (19) evaluated in a cohort of 164 CD patients the relationship between endoscopic (measured by SES-CD) and clinical disease activity (CDAI) and serum (high-sensitivity CRP, interleukin-6) and fecal biomarkers (calprotectin and lactoferrin) . In accordance to the above cited studies, they reported signifi cant correlations of SES-CD with fecal and serum biomarkers. However, this stands in contrast to the above cited reports, they found no correlation between SES-CD and CDAI.
Th e question may arise if it is necessary at all to assess the extent of mucosal damage and if it is not suffi cient to treat CD patients solely with the focus on clinical remission. Th e CDAI, mainly based on symptoms, has an insuffi cient ability to detect low-grade mucosal infl ammation. We found that CDAI was unable to discriminate between inactive vs. mild and mild vs. moderate endoscopic activity; of note, the sensitivity of CDAI for detection of endoscopically active disease was only 33 % . Similar fi ndings were reported in the study of Sipponen et al. (20) . Th us, caution should be exercised when interpreting CDAI data in relation to endoscopic activity. Furthermore, certain items of the CDAI vary because of individual particularities, such as a variable weekly stool frequency e.g., if irritable bowel symptoms are superimposed on CD activity. Such irritable bowel syndrome like symptoms have been reported in two to three times higher frequency in IBD patients in remission compared with the normal population (25) . In addition, anti-infl ammatory therapy is associated with a reduction of CD-related hospitalizations and surgical procedures (26, 27) . Th ereby, achievement of mucosal healing may alter the natural course of the disease. Th e established symptom-based therapeutic concept (by measuring CDAI) should therefore be reconsidered. Whether mucosal healing is defi nitely a therapeutic goal in the treatment of CD remains to be proven in further prospective studies evaluating disease outcome, but at least, the assessment of mucosal healing should be included in clinical trials as an important outcome variable. As fecal calprotectin closely correlates with endoscopically assessed mucosal damage and as patient ' s acceptance for fecal sampling is high (28) this biomarker should be useful to monitor the extent of mucosal damage in CD.
It should be kept in mind that fecal calprotectin is an unspecifi c biomarker and may be elevated in non-IBD related infl ammations such as bacterial or drug-induced enterocolitis (28) . Endoscopy has an established role in CD assessment especially if the disease course deteriorates under therapy (search for CMV gastrointestinal tract and small bowel because this would have represented an imbalance between diagnostic expenses on one hand and expected yield on the other. We tried to reduce the inevitable diagnostic blurring by off ering upper endoscopies to CD patients with symptoms compatible of upper gastrointestinal tract CD. Fourth, there exists no consensus defi nition on the endoscopic activity so far. Th erefore, our applied defi nitions of the diff erent stages of endoscopic activity represent only a consensus within our study group and does not claim to have universal validation. In summary, we demonstrated that fecal calprotectin was the only marker that could reliably discriminate inactive from mild, moderate, and high endoscopic activity. Th erefore, fecal calprotectin has the potential to replace endoscopy in the disease monitoring of CD. Measuring the CDAI is inappropriate for assessment of endoscopic infl ammatory activity.
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super infection). However, for monitoring the extent of mucosal damage, fecal calprotectin as a noninvasive and cheap biomarker seems to be a reliable and convenient alternative (29) .
Our results with elevated CRP to detect endoscopically active disease are in agreement with an earlier publication of our group and also compare well with the results of Sipponen et al. (17, 20) . Polymorphisms in the CRP gene can be responsible for interindividual diff erences in CRP production in humans (30) . Assessment of blood leukocytosis for detection of active endoscopic disease has obviously limitations; these may be explained by the fact that CD patients are usually under therapy with immunomodulators or steroids that both can aff ect absolute leukocyte counts.
Our study has several potential limitations. Th e fi rst may be our decision not to assess further fecal leukocyte markers besides calprotectin. We voted against the inclusion of lactoferrin because we have assessed this marker in two recent studies and found the results to be comparable with calprotectin (12, 28) . We further omitted the determination of poly-morphonuclear-elastase in feces because a well-conducted trial again demonstrated similar results with calprotecctin and lactoferrin for the detection of active endoscopic disease (15) . Second, the topic of mucosal healing is controversially discussed and available data on the signifi cance in CD are so far limited. Despite that, our results provide evidence that mucosal healing can noninvasively be measured by calprotectin as a surrogate marker. Th ird, an ileocolonoscopy may not be suffi cient to detect the whole extent of CD. In the absence of symptoms, we did not carry out a systematic search for CD involvement of the upper 
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WHAT IS CURRENT KNOWLEDGE
3 There is a need for noninasive markers assessing endoscopic Crohn ' s disease activity.
